{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T20:11:10Z","timestamp":1694635870494},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2009,5,31]],"date-time":"2009-05-31T00:00:00Z","timestamp":1243728000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Heart Fail Rep"],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1007\/s11897-009-0017-5","type":"journal-article","created":{"date-parts":[[2009,5,30]],"date-time":"2009-05-30T09:46:02Z","timestamp":1243676762000},"page":"112-116","source":"Crossref","is-referenced-by-count":2,"title":["Multiple renin-angiotensin-aldosterone-blocking agents in heart failure: How much is too much?"],"prefix":"10.1007","volume":"6","author":[{"given":"Bertram","family":"Pitt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,5,31]]},"reference":[{"key":"17_CR1","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S0140-6736(02)09895-1","volume":"360","author":"K. Dickstein","year":"2002","unstructured":"Dickstein K, Kjekshus J: Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002, 360:752\u2013760.","journal-title":"Lancet"},{"key":"17_CR2","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","volume":"349","author":"M.A. Pfeffer","year":"2003","unstructured":"Pfeffer MA, McMurray JJ, Velazquez EJ, et al.: Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003, 349:1893\u20131906. [Published erratum appears in N Engl J Med 2004, 350:203.]","journal-title":"N Engl J Med"},{"key":"17_CR3","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","volume":"358","author":"S. Yusuf","year":"2008","unstructured":"Yusuf S, Teo KK, Pogue J, et al.: Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008, 358:1547\u20131559.","journal-title":"N Engl J Med"},{"key":"17_CR4","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S0140-6736(00)02213-3","volume":"355","author":"B. Pitt","year":"2000","unstructured":"Pitt B, Poole-Wilson PA, Segal R, et al.: Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 2000, 355:1582\u20131587.","journal-title":"Lancet"},{"key":"17_CR5","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","volume":"345","author":"J.N. Cohn","year":"2001","unstructured":"Cohn JN, Tognoni G: A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001, 345:1667\u20131675.","journal-title":"N Engl J Med"},{"key":"17_CR6","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(03)14283-3","volume":"362","author":"J.J. McMurray","year":"2003","unstructured":"McMurray JJ, Ostergren J, Swedberg K, et al.: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003, 362:767\u2013771.","journal-title":"Lancet"},{"key":"17_CR7","doi-asserted-by":"crossref","unstructured":"Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group [no authors listed]. Circulation 1998, 97:2202\u20132212.","DOI":"10.1161\/01.CIR.97.22.2202"},{"key":"17_CR8","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0002-9343(03)00435-2","volume":"115","author":"E.J. Rodrigues","year":"2003","unstructured":"Rodrigues EJ, Eisenberg MJ, Pilote L: Effects of early and late administration of angiotensin-converting enzyme inhibitors on mortality after myocardial infarction. Am J Med 2003, 115:473\u2013479.","journal-title":"Am J Med"},{"key":"17_CR9","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1161\/01.CIR.95.12.2643","volume":"95","author":"M.A. Pfeffer","year":"1997","unstructured":"Pfeffer MA, Greaves SC, Arnold JM, et al.: Early versus delayed angiotensin-converting enzyme inhibition therapy in acute myocardial infarction. The healing and early afterload reducing therapy trial. Circulation 1997, 95:2643\u20132651.","journal-title":"Circulation"},{"key":"17_CR10","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/S0002-9149(99)80753-X","volume":"75","author":"M.A. Pfeffer","year":"1995","unstructured":"Pfeffer MA, Hennekens CH: When a question has an answer: rationale for our early termination of the HEART Trial. Am J Cardiol 1995, 75:1173\u20131175.","journal-title":"Am J Cardiol"},{"key":"17_CR11","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1161\/01.CIR.92.10.3132","volume":"92","author":"R. Latini","year":"1995","unstructured":"Latini R, Maggioni AP, Flather M, et al.: ACE inhibitor use in patients with myocardial infarction. Summary of evidence from clinical trials. Circulation 1995, 92:3132\u20133137.","journal-title":"Circulation"},{"key":"17_CR12","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.ejheart.2004.09.005","volume":"6","author":"H. Krum","year":"2004","unstructured":"Krum H, Carson P, Farsang C, et al.: Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFT. Eur J Heart Fail 2004, 6:937\u2013945.","journal-title":"Eur J Heart Fail"},{"key":"17_CR13","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.ahj.2006.02.028","volume":"151","author":"J.J. McMurray","year":"2006","unstructured":"McMurray JJ, Young JB, Dunlap ME, et al.: Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial. Am Heart J 2006, 151:985\u2013991.","journal-title":"Am Heart J"},{"key":"17_CR14","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.cardfail.2007.11.008","volume":"14","author":"R. Lakhdar","year":"2008","unstructured":"Lakhdar R, Al-Mallah MH, Lanfear DE: Safety and tolerability of angiotensin-converting enzyme inhibitor versus the combination of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker in patients with left ventricular dysfunction: a systematic review and meta-analysis of randomized controlled trials. J Card Fail 2008, 14:181\u2013188.","journal-title":"J Card Fail"},{"key":"17_CR15","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","volume":"372","author":"J.F. Mann","year":"2008","unstructured":"Mann JF, Schmieder RE, McQueen M, et al.: Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008, 372:547\u2013553.","journal-title":"Lancet"},{"key":"17_CR16","doi-asserted-by":"crossref","first-page":"16","DOI":"10.7326\/0003-4819-148-1-200801010-00189","volume":"148","author":"D.B. Matchar","year":"2008","unstructured":"Matchar DB, McCrory DC, Orlando LA, et al.: Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med 2008, 148:16\u201329.","journal-title":"Ann Intern Med"},{"key":"17_CR17","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.cardfail.2008.03.003","volume":"14","author":"G. Mak","year":"2008","unstructured":"Mak G, Murphy NF, Ali A, et al.: Multiple neurohumoral modulating agents in systolic dysfunction heart failure: are we lowering blood pressure too much? J Card Fail 2008, 14:555\u2013560.","journal-title":"J Card Fail"},{"key":"17_CR18","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B. Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999, 341:709\u2013717.","journal-title":"N Engl J Med"},{"key":"17_CR19","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B. Pitt","year":"2003","unstructured":"Pitt B, Remme W, Zannad F, et al.: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309\u20131321. [Published erratum appears in N Engl J Med 2003, 348:2271.]","journal-title":"N Engl J Med"},{"key":"17_CR20","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1161\/ATVBAHA.108.168021","volume":"28","author":"A.C. Montezano","year":"2008","unstructured":"Montezano AC, Callera GE, Yogi A, et al.: Aldosterone and angiotensin II synergistically stimulate migration in vascular smooth muscle cells through c-Src-regulated redox-sensitive RhoA pathways. Arterioscler Thromb Vasc Biol 2008, 28:1511\u20131518.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"17_CR21","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1161\/01.CIR.0000091405.00772.6E","volume":"108","author":"B. Pitt","year":"2003","unstructured":"Pitt B, Reichek N, Willenbrock R, et al.: Effects of eplerenone, enalapril, and eplerenone\/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 2003, 108:1831\u20131838.","journal-title":"Circulation"},{"key":"17_CR22","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1161\/01.CIR.0000086776.15268.22","volume":"108","author":"B. Pitt","year":"2003","unstructured":"Pitt B: Aldosterone blockade in patients with systolic left ventricular dysfunction. Circulation 2003, 108:1790\u20131794.","journal-title":"Circulation"},{"issue":"Suppl","key":"17_CR23","first-page":"227A","volume":"A","author":"J. Banas","year":"2006","unstructured":"Banas J: Absence of clinical hypotension with eplerenone in post acute myocardial infarction patients with heart failure and left ventricular systolic dysfunction. Results from Ephesus. Am J Cardiol 2006, A(Suppl):227A.","journal-title":"Am J Cardiol"},{"key":"17_CR24","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1161\/CIRCHEARTFAILURE.107.740704","volume":"1","author":"J. McMurray","year":"2008","unstructured":"McMurray J, Pitt B, Latini R, et al.: Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail 2008, 1:17\u201324.","journal-title":"Circ Heart Fail"},{"key":"17_CR25","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1161\/circ.116.suppl_16.II_549-a","volume":"116","author":"B. Pitt","year":"2007","unstructured":"Pitt B, McMurray J, Latini R, et al.: Heart failure: neurohormonal modulation [abstract]. Circulation 2007, 116:2491.","journal-title":"Circulation"},{"key":"17_CR26","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1681\/ASN.2004100874","volume":"16","author":"N.D. Fisher","year":"2005","unstructured":"Fisher ND, Hollenberg NK: Renin inhibition: what are the therapeutic opportunities? J Am Soc Nephrol 2005, 16:592\u2013599.","journal-title":"J Am Soc Nephrol"}],"container-title":["Current Heart Failure Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-009-0017-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11897-009-0017-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-009-0017-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,6]],"date-time":"2021-10-06T13:55:21Z","timestamp":1633528521000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11897-009-0017-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5,31]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["17"],"URL":"https:\/\/doi.org\/10.1007\/s11897-009-0017-5","relation":{},"ISSN":["1546-9530","1546-9549"],"issn-type":[{"value":"1546-9530","type":"print"},{"value":"1546-9549","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,5,31]]}}}